Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Negative Sentiment
Dr. Fathi presents the latest KOMET-001 data
Key Takeaway: The article titled 'Dr. Fathi presents the latest KOMET-001 data' is currently inaccessible due to a verification check. As a result, no specific details or findings from the KOMET-001 study are available for review. This limitation hinders the ability to assess the significance of the presented data.
Price reaction · baseline $9.59 (2023-09-18 close) · hit pre-market · clean, no other KURA news in the window
day 0 close · peak
+0.4%
Market Sentiment Analysis
CONCERNS & RISKS
- The article does not provide any specific data or insights from the KOMET-001 study.
- The content is interrupted by a verification prompt, limiting access to the information.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic